We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+5.74%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.25B
AUM Growth
-$166M
Cap. Flow
+$57.7M
Cap. Flow %
2.57%
Top 10 Hldgs %
71.88%
Holding
46
New
3
Increased
7
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
GNCA
Genocea Biosciences, Inc.
GNCA
+$26M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$14.3M
3
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$13.2M
4
ADAP
Adaptimmune Therapeutics
ADAP
+$11.4M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$10.9M

Top Sells

Rank Stock Value
1
CASC
Cascadian Therapeutics, Inc.
CASC
+$33.5M
2
ORKA
Oruka Therapeutics
ORKA
+$1.97M
3
OREX
Orexigen Therapeutics, Inc.
OREX
+$478K

Sector Composition

Rank Sector Weight
1 Healthcare 91.74%
2 Technology 1.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$595M 26.49%
10,420,555
+145,442
+1% +$9.36M
CRSP icon
2
CRISPR Therapeutics
CRSP
$4.66B
$159M 7.08%
3,484,464
+263,736
+8% +$10.9M
ADAP
3
DELISTED
Adaptimmune Therapeutics
ADAP
$150M 6.66%
13,332,611
+1,306,612
+11% +$11.4M
CBIO
4
Crescent Biopharma
CBIO
$576M
$139M 6.2%
85,841
– –
MRSN
5
DELISTED
Mersana Therapeutics
MRSN
$128M 5.71%
325,771
– –
EPZM
6
DELISTED
Epizyme, Inc
EPZM
$115M 5.1%
6,460,851
– –
RYTM icon
7
Rhythm Pharmaceuticals
RYTM
$7.36B
$97.8M 4.35%
4,912,306
– –
SENS icon
8
Senseonics Holdings Inc
SENS
$258M
$92.7M 4.12%
1,544,413
– –
ARDX icon
9
Ardelyx
ARDX
$1.25B
$71.1M 3.16%
14,083,582
– –
AKAO
10
DELISTED
Achaogen Inc
AKAO
$67.5M 3%
5,215,128
– –
OBSV
11
DELISTED
ObsEva SA Ordinary Shares
OBSV
$61.9M 2.75%
4,586,563
– –
AVEO
12
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$47.5M 2.11%
1,636,269
– –
XFOR icon
13
X4 Pharmaceuticals
XFOR
$376M
$45.8M 2.04%
11,111
– –
IMMU
14
DELISTED
Immunomedics Inc
IMMU
$40.5M 1.8%
2,772,643
– –
SYBX
15
DELISTED
Synlogic
SYBX
$39.7M 1.76%
281,961
+27,334
+11% +$4.24M
SBBP
16
DELISTED
Strongbridge Biopharma plc.
SBBP
$36.7M 1.63%
4,141,308
– –
CMTA
17
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$32.4M 1.44%
2,141,697
– –
RARX
18
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$29.2M 1.3%
5,493,636
+2,000,000
+57% +$14.3M
DERM
19
DELISTED
Dermira, Inc.
DERM
$28M 1.25%
3,506,649
– –
KA
20
DELISTED
Kineta, Inc. Common Stock
KA
$26.4M 1.17%
39,691
– –
GNCA
21
DELISTED
Genocea Biosciences, Inc.
GNCA
$26.3M 1.17%
+3,125,000
New +$26M
AUPH icon
22
Aurinia Pharmaceuticals
AUPH
$1.92B
$25M 1.11%
4,808,483
– –
VRNA
23
DELISTED
Verona Pharma
VRNA
$24.4M 1.09%
1,219,674
– –
LXRX icon
24
Lexicon Pharmaceuticals
LXRX
$1.03B
$20.4M 0.91%
2,382,286
– –
CTIC
25
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$14.6M 0.65%
+3,750,000
New +$13.2M
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q1 2018 Portfolio in Review

As of Q1 2018, NEA Management Company held 46 positions worth $2.25B, down 6.9% from $2.41B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

NEA Management Company's Q1 2018 filing shows 3 new, 7 increased and 3 closed positions. Its largest new stake was Genocea Biosciences, Inc.: 3,125,000 shares worth $26.3M. The largest sale was Cascadian Therapeutics, Inc., an estimated $33.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier, followed by Technology.

  • NEA Management Company's largest Q1 2018 buy was Genocea Biosciences, Inc.: 3,125,000 shares worth $26.3M.
  • NEA Management Company added most to Ra Pharmaceuticals, Inc. Common Stock in Q1 2018, an estimated $14.3M increase.
  • NEA Management Company fully exited Cascadian Therapeutics, Inc. in Q1 2018, selling an estimated $33.5M.
  • NEA Management Company's ten largest holdings make up 72% of its $2.25B portfolio in Q1 2018.
  • NEA Management Company opened 3 new positions and closed 3 in Q1 2018.
  • NEA Management Company's portfolio value fell 6.9% quarter-over-quarter to $2.25B.

Based on NEA Management Company's 13F filing for Q1 2018, filed 10 May 2018.